Marcel Weber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9144574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Silent and Apparent Cerebral Ischemia After Percutaneous Transfemoral Aortic Valve Implantation. Circulation, 2010, 121, 870-878.	1.6	483
2	Transcatheter Versus Medical Treatment of Patients With Symptomatic SevereÂTricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 74, 2998-3008.	2.8	302
3	Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, The, 2019, 394, 2002-2011.	13.7	283
4	Transcatheter Edge-to-Edge RepairÂforÂTreatment of TricuspidÂRegurgitation. Journal of the American College of Cardiology, 2021, 77, 229-239.	2.8	247
5	6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With SevereÂTricuspidÂRegurgitation. Journal of the American College of Cardiology, 2019, 73, 1905-1915.	2.8	172
6	1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic TricuspidÂRegurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1451-1461.	2.9	160
7	Evaluation of Posttraumatic Cerebral Blood Flow Velocities by Transcranial Doppler Ultrasonography. Neurosurgery, 1990, 27, 106-112.	1.1	135
8	Compassionate Use of the PASCAL Transcatheter Valve Repair System for Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 2488-2495.	2.9	109
9	Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention, 2021, 16, e1264-e1271.	3.2	100
10	Vascular Access Site Complications after Percutaneous Transfemoral Aortic Valve Implantation. Herz, 2009, 34, 398-408.	1.1	96
11	Intravascular Lithotripsy in Calcified Coronary Lesions. Circulation: Cardiovascular Interventions, 2019, 12, e008154.	3.9	69
12	Combined Tricuspid and Mitral VersusÂlsolatedÂMitral Valve RepairÂforÂSevereÂMR and TR. JACC: Cardiovascular Interventions, 2020, 13, 543-550.	2.9	63
13	Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome. JACC: Cardiovascular Interventions, 2020, 13, 1251-1261.	2.9	52
14	Three-Dimensional Speckle-Tracking Analysis of Left Ventricular Function after Transcatheter Aortic Valve Implantation. Journal of the American Society of Echocardiography, 2012, 25, 827-834.e1.	2.8	51
15	Acute Changes of Mitral Valve Geometry During Interventional Edge-to-Edge Repair With the MitraClip System Are Associated With Midterm Outcomes in Patients With Functional Valve Disease. Circulation: Cardiovascular Interventions, 2014, 7, 390-399.	3.9	51
16	Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. American Heart Journal, 2015, 170, 821-829.	2.7	43
17	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2020, 13, 1999-2009.	2.9	42
18	Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention, 2021, 17, e343-e352.	3.2	41

#	Article	IF	CITATIONS
19	Recurrent Mitral Regurgitation After MitraClip: Predictive Factors, Morphology, and Clinical Implication. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010895.	3.9	34
20	Pre-Procedural Hemodynamic Status Improves the Discriminatory Value ofÂtheÂAortic Regurgitation Index in Patients Undergoing Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 700-711.	2.9	33
21	Periprocedural Myocardial Injury Depends onÂTranscatheter Heart Valve Type But DoesÂNotÂPredict Mortality in Patients After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1550-1560.	2.9	33
22	Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study. EuroIntervention, 2021, 17, 809-817.	3.2	33
23	Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a realâ€world multicentre experience. European Journal of Heart Failure, 2022, 24, 899-907.	7.1	33
24	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. JACC: Cardiovascular Interventions, 2020, 13, 554-564.	2.9	32
25	Leaflet Configuration and Residual Tricuspid Regurgitation After Transcatheter Edge-to-Edge TricuspidÂRepair. JACC: Cardiovascular Interventions, 2021, 14, 2260-2270.	2.9	30
26	12â€Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation. Catheterization and Cardiovascular Interventions, 2021, 97, 1281-1289.	1.7	29
27	Impact of coronary artery disease in patients undergoing transfemoral transcatheter aortic valve implantation. International Journal of Cardiology, 2017, 245, 215-221.	1.7	28
28	Safety and Efficacy of Protamine Administration for Prevention of BleedingÂComplications in Patients Undergoing TAVR. JACC: Cardiovascular Interventions, 2020, 13, 1471-1480.	2.9	28
29	Impact of left ventricular conduction defect with or without need for permanent right ventricular pacing on functional and clinical recovery after TAVR. Clinical Research in Cardiology, 2015, 104, 964-974.	3.3	27
30	Impact of the Leaflet-to-Annulus Index on Residual Mitral Regurgitation in Patients Undergoing Edge-to-Edge Mitral Repair. JACC: Cardiovascular Interventions, 2019, 12, 2462-2472.	2.9	26
31	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e009685.	3.9	26
32	Impact of interventional edge-to-edge repair on mitral valve geometry. International Journal of Cardiology, 2017, 230, 468-475.	1.7	22
33	PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis. Clinical Research in Cardiology, 2021, 110, 451-459.	3.3	18
34	Early versus newer generation transcatheter heart valves for transcatheter aortic valve implantation: Echocardiographic and hemodynamic evaluation of an all-comers study cohort using the dimensionless aortic regurgitation index (AR-index). PLoS ONE, 2019, 14, e0217544.	2.5	17
35	Long-term follow-up after stent graft placement for access-site and access-related vascular injury during TAVI – The Bonn-Copenhagen experience. International Journal of Cardiology, 2019, 281, 42-46.	1.7	17
36	Balloon post-dilation and valve-in-valve implantation for the reduction of paravalvular leakage with use of the self-expanding CoreValve prosthesis. EuroIntervention, 2016, 11, 1140-1147.	3.2	17

#	Article	IF	CITATIONS
37	Impact of Tricuspid Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1135-1137.	2.9	12
38	Clinical outcomes and thrombus resolution in patients with solid left atrial appendage thrombi: results of a single-center real-world registry. Clinical Research in Cardiology, 2021, 110, 72-83.	3.3	12
39	Permanent Pacemaker Implantation after TAVR – Predictors and Impact on Outcomes. Interventional Cardiology Review, 2015, 10, 98.	1.6	12
40	Leaflet edge-to-edge treatment versus direct annuloplasty in patients with functional mitral regurgitation. EuroIntervention, 2019, 15, 912-918.	3.2	12
41	Staged transcatheter valve repair via MitraClip XTR after Cardioband for tricuspid regurgitation. European Heart Journal Cardiovascular Imaging, 2019, 20, 118-118.	1.2	11
42	Feasibility of CT-derived myocardial strain measurement in patients with advanced cardiac valve disease. Scientific Reports, 2021, 11, 8793.	3.3	11
43	Fractional flow reserve in patients with coronary artery disease undergoing TAVI: a prospective analysis. Clinical Research in Cardiology, 2020, 109, 746-754.	3.3	10
44	Three-dimensional imaging of the aortic valve geometry for prosthesis sizing prior to transcatheter aortic valve replacement. International Journal of Cardiology, 2014, 174, 844-849.	1.7	9
45	Speckle tracking echocardiography in chronic obstructive pulmonary disease and overlapping obstructive sleep apnea. International Journal of COPD, 2016, Volume 11, 1823-1834.	2.3	9
46	Novel approaches for prevention of stroke related to transcatheter aortic valve implantation. Expert Review of Cardiovascular Therapy, 2013, 11, 1311-1320.	1,5	8
47	Impact of cancer history on clinical outcome in patients undergoing transcatheter edge-to-edge mitral repair. Clinical Research in Cardiology, 2021, 110, 440-450.	3.3	8
48	Successful Edge-to-Edge Mitral Repair Using the New MitraClip XTR System Following Rupture of Transapical Implanted NeoChord. JACC: Cardiovascular Interventions, 2018, 11, e175-e177.	2.9	7
49	Prognostic impact of hepatorenal function in patients undergoing transcatheter tricuspid valve repair. Scientific Reports, 2021, 11, 14420.	3.3	7
50	Outcomes of myocardial fibrosis in patients undergoing transcatheter aortic valve replacement. EuroIntervention, 2020, 15, 1417-1423.	3.2	7
51	Prognostic Impact of Redo Transcatheter Mitral Valve Repair for Recurrent Mitral Regurgitation. American Journal of Cardiology, 2020, 130, 123-129.	1.6	6
52	Comparison of different imaging modalities for the quantification of tricuspid valve geometry and regurgitation: a retrospective, singleâ€eenter study. Health Science Reports, 2020, 3, e159.	1.5	6
53	Use of Pre- and Intensified Postprocedural Physiotherapy in Patients with Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Study (the 4P-TAVR Study). Journal of Interventional Cardiology, 2021, 2021, 1-8.	1.2	6
54	A novel scoring system to estimate chemotherapy-induced myocardial toxicity: Risk assessment prior to non-anthracycline chemotherapy regimens. IJC Heart and Vasculature, 2021, 33, 100751.	1.1	6

#	Article	IF	CITATIONS
55	Impact of right ventricular-pulmonary arterial coupling on clinical outcomes of tricuspid regurgitation. EuroIntervention, 2022, 18, 852-861.	3.2	6
56	Sympathetic Activity in Patients WithÂSecondary Symptomatic MitralÂRegurgitation or End-Stage SystolicÂHeart Failure. JACC: Cardiovascular Interventions, 2016, 9, 2050-2057.	2.9	5
57	Impact of Coronary Artery Disease on Outcomes in Patients Undergoing Percutaneous Edge-to-Edge Repair. JACC: Cardiovascular Interventions, 2020, 13, 2137-2145.	2.9	5
58	TAVR outcome after reclassification of aortic valve stenosis by using a hybrid continuity equation that combines computed tomography and echocardiography data. Catheterization and Cardiovascular Interventions, 2020, 96, 958-967.	1.7	5
59	Combination of high-sensitivity C-reactive protein with logistic EuroSCORE improves risk stratification in patients undergoing TAVI. EuroIntervention, 2018, 14, 629-636.	3.2	5
60	Early response of right-ventricular function to percutaneous mitral valve repair. Clinical Research in Cardiology, 2022, 111, 859-868.	3.3	5
61	Frailty, malnutrition, and the endocrine system impact outcome in patients undergoing aortic valve replacement. Catheterization and Cardiovascular Interventions, 2022, 99, 145-157.	1.7	4
62	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Canadian Journal of Cardiology, 2021, 37, 1094-1102.	1.7	4
63	Noninvasive model including right ventricular speckle tracking for the evaluation of pulmonary hypertension. World Journal of Cardiology, 2016, 8, 472.	1.5	4
64	Haemodynamic differences between two generations of a balloon-expandable transcatheter heart valve. Heart, 2022, 108, 1479-1485.	2.9	4
65	Percutaneous trans-axilla transcatheter aortic valve replacement. Heart and Vessels, 2022, 37, 1801-1807.	1.2	4
66	Assessment of LAA Strain and Thrombus Mobility and Its Impact on Thrombus Resolution—Added-Value of a Novel Echocardiographic Thrombus Tracking Method. Cardiovascular Engineering and Technology, 2022, , 1.	1.6	4
67	Combined Percutaneous Therapy for Tricuspid Regurgitation Using the Cardioband and PASCAL System inÂ1ÂProcedure. JACC: Cardiovascular Interventions, 2019, 12, e197-e198.	2.9	3
68	Pulmonary capillary wedge pressure (PCWP) as prognostic indicator in patients undergoing transcatheter valve repair (TTVR) of severe tricuspid regurgitation. International Journal of Cardiology, 2020, 318, 32-38.	1.7	3
69	Prognostic significance of the get with the guidelines-heart failure (GWTG-HF) risk score in patients undergoing trans-catheter tricuspid valve repair (TTVR). Heart and Vessels, 2021, 36, 1903-1910.	1.2	3
70	The predictive value of intraprocedural mitral gradient for outcomes after MitraClip and its periâ€interventional dynamics. Echocardiography, 2021, 38, 1115-1124.	0.9	3
71	Baseline PA/BSA ratio in patients undergoing transcatheter aortic valve replacement – A novel CT-based marker for the prediction of pulmonary hypertension and outcome. International Journal of Cardiology, 2022, 348, 26-32.	1.7	3
72	NeoChord System as an Alternative Option Upon Transmitral Pressure Gradient Elevation in the MitraClipÂProcedure. JACC: Cardiovascular Interventions, 2020, 13, e39-e40.	2.9	2

#	Article	IF	CITATIONS
73	Transcatheter tricuspid intervention: ready for primetime?. Heart, 2022, 108, 479-491.	2.9	2
74	Left atrial function index (LAFI) and outcome in patients undergoing transcatheter aortic valve replacement. Clinical Research in Cardiology, 2022, 111, 944-954.	3.3	2
75	A staging classification of right heart remodelling for patients undergoing transcatheter edge-to-edge mitral valve repair. EuroIntervention, 2022, 18, 43-49.	3.2	2
76	Predictive value of the Fibrosis-4 index in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Clinical Research in Cardiology, 2022, 111, 1367-1376.	3.3	2
77	Association of heart failure duration with clinical outcomes after transcatheter mitral valve repair for functional mitral regurgitation. Catheterization and Cardiovascular Interventions, 2020, 98, E412-E419.	1.7	1
78	The modified MIDA-Score predicts mid-term outcomes after interventional therapy of functional mitral regurgitation. PLoS ONE, 2020, 15, e0236265.	2.5	1
79	Impact of combined baseline and postprocedural troponin values on clinical outcome following the MitraClip procedure. Catheterization and Cardiovascular Interventions, 2020, 96, E735-E743.	1.7	1
80	Transcatheter Triple-Valve Intervention. JACC: Cardiovascular Interventions, 2021, 14, e179-e181.	2.9	1
81	Trikuspidalinsuffizienz: Die vernachlÄ z sigte Klappe. , 0, , .		1
82	Provisional Closure of an Iatrogenic Atrial Septal Defect for Shunt Reversal After Transcatheter Treatment of Tricuspid Regurgitation. Journal of Invasive Cardiology, 2019, 31, E298-E299.	0.4	1
83	Transapical transcatheter aortic valve replacement with simultaneous paravalvular leakage closure in a patient with severely degenerated aortic valve bioprosthesis. European Heart Journal Cardiovascular Imaging, 2014, 15, 1058-1058.	1.2	Ο
84	Another Piece in the Tricuspid Puzzle. JACC: Cardiovascular Interventions, 2019, 12, 1435-1437.	2.9	0
85	COPD Does Not Corrupt COAPT. JACC: Cardiovascular Interventions, 2020, 13, 2804-2805.	2.9	Ο
86	Aortic Valve Deformation During Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1603-1604.	2.9	0
87	QRS duration is a risk indicator of adverse outcomes after MitraClip. Catheterization and Cardiovascular Interventions, 2021, 98, E594-E601.	1.7	0
88	Transcatheter Leaflet Strategies for Tricuspid Regurgitation TriClip and CLASP. Interventional Cardiology Clinics, 2022, 11, 51-66.	0.4	0
89	Title is missing!. , 2020, 15, e0236265.		0
90	Title is missing!. , 2020, 15, e0236265.		0

#	Article	IF	CITATIONS
91	Title is missing!. , 2020, 15, e0236265.		Ο
92	Title is missing!. , 2020, 15, e0236265.		0
93	Title is missing!. , 2020, 15, e0236265.		0
94	Title is missing!. , 2020, 15, e0236265.		0